Form 4: VTV Therapeutics Director Exchanges Common Stock for Pre-Funded Warrants

A VTV Therapeutics director, Srinivas Akkaraju, through Samsara BioCapital, L.P., exchanged 58,836 shares of Class A Common Stock for pre-funded warrants exercisable for 58,885 shares at $0.01 per share.

Summary

• On March 5, 2024, Samsara BioCapital, L.P., an entity associated with VTV Therapeutics director Srinivas Akkaraju, exchanged 58,836 shares of Class A Common Stock for pre-funded warrants.
• The pre-funded warrants are exercisable for up to 58,885 shares of Class A Common Stock at an exercise price of $0.01 per share.
• The exchange was made with no additional consideration.
• The pre-funded warrants have no expiration date and can be exercised at any time after issuance.
• The holder of the pre-funded warrants cannot exercise them if it would result in beneficial ownership of more than 9.99% of the outstanding Class A Common Stock.

Sentiment

Score: 7

Explanation: The document describes a routine transaction, not indicative of any major positive or negative sentiment. The exchange of stock for warrants is a neutral event.

Positives

• The exchange of common stock for pre-funded warrants provides flexibility for the holder.
• The low exercise price of $0.01 per share for the warrants is favorable for the holder.

Risks

• The holder of the pre-funded warrants is limited in their ability to exercise the warrants if it would result in beneficial ownership of more than 9.99% of the outstanding Class A Common Stock.

Industry Context

This transaction is a common practice for directors and major shareholders to manage their holdings and potential future ownership in a company.

Comparison to Industry Standards

• The use of pre-funded warrants is a relatively common method for companies to raise capital or manage ownership structures.
• The specific terms of the warrants, such as the exercise price and ownership limitations, are typical in such agreements.
• Similar transactions can be seen in other biotech and pharmaceutical companies where directors and major shareholders adjust their holdings.

Related Party Transactions

• The transaction involves Samsara BioCapital, L.P., an entity related to director Srinivas Akkaraju.

Stakeholder Impact

• The transaction has a minor impact on shareholders as it involves a change in the form of ownership for a specific number of shares, not a change in the total number of shares outstanding.
• The transaction does not directly impact employees, customers, suppliers, or creditors.

Key Dates

Keywords

pre-funded warrants, Class A Common Stock, Samsara BioCapital, Srinivas Akkaraju, VTV Therapeutics, beneficial ownership, exchange agreement